Therefore, this case report suggests that genetic evaluation of TCR pathway molecules and assessment of PD-1 expression on malignant T cells may be required as a method for identifying patients with T cell lymphoma who might experience progression upon PD-1 blockade treatment. Here, PDCD1 is linked to T-cell non-Hodgkin lymphoma.